Back to Search Start Over

Supplementary Tables 1-11 from HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma

Authors :
Keiran S.M. Smalley
J. William Harbour
Jonathan D. Licht
Uwe Rix
Silvya Stuchi Maria-Engler
Srikumar P. Chellappan
John M. Koomen
Bin Fang
Biswarup Saha
Fumi Kinose
Michael A. Durante
Michael F. Emmons
Fernanda Faião-Flores
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Supplementary Table S1- Antibodies used for protein expression in western blotting experiments Supplementary Table S2 - Assays used for gene expression in RT-qPCR experiments Supplementary Table S3 - Antibodies used for protein expression in immunofluorescence experiments Supplementary Table S4 - Inhibitory concentration 50% (IC50) of MEKi after 72h in uveal melanoma cell lines (nM) Supplementary Table S5 - Members of the GSEA GO_REGULATION_OF_PHOSPHATIDYLINOSITOL_3_KINASE_SIGNALING family Supplementary Table S6 - Members of the GSEA GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_KINASE_ACTIVITY family Supplementary Table S7 - Members of the GSEA GO_TRANSMEMBRANE_RECEPTOR_PROTEIN_TYROSINE_KINASE_ACTIVITY family Supplementary Table S8 - Members of the GSEA HIPPO_TARGETS family Supplementary Table S9 - Members of the GSEA REACTOME_GPCR_LIGAND_BINDING Family Supplementary Table S10 - Compounds used in the drug screening Supplementary Table S11 - Members of the GSEA HALLMARK_PI3K_AKT_MTOR_SIGNALING

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....20b6fa70918d2735b28b48bcd1f4dcb8